Hansen Medical's Magellan(TM) Robotic System to Be Featured in Three Live Cases at 26th Annual International Symposium on End...
20 1월 2014 - 8:00PM
Marketwired
Hansen Medical's Magellan(TM) Robotic System to Be Featured in
Three Live Cases at 26th Annual International Symposium on
Endovascular Therapy
MOUNTAIN VIEW, CA--(Marketwired - Jan 20, 2014) - Hansen
Medical, Inc. (NASDAQ: HNSN), a global leader in Intravascular
Robotics, today announced that Dr. Barry Katzen, founder and
Medical Director of Baptist Cardiac & Vascular Institute
(Baptist Hospital of Miami), is scheduled to utilize the Magellan™
Robotic System in three live endovascular cases at the
26th Annual International Symposium on Endovascular
Therapy (ISET), from January 18th - 22nd at the Fontainebleau Miami
Beach Hotel in Miami, FL. The Company will also be exhibiting the
Magellan Robotic System during the meeting at Booth 603.
Dr. Katzen, a course director at ISET, plans to utilize the
Magellan Robotic System during one case scheduled for Monday,
January 20th at 1:00 pm, and two additional cases on Tuesday,
January 21st, at 8:00 am and 1:00 pm, respectively.
Additionally, Dr. Constantino Peña of Baptist Cardiac &
Vascular Institute will deliver a Magellan themed
presentation, titled "Robotics in Peripheral Intervention" during
the "Nurses & Technologists Symposium: Innovations in Cardiac
and Vascular Care" session on Saturday, January 18th at 11:00
am.
"We are pleased that Dr. Katzen will showcase the Magellan
Robotic System at ISET, which is in its 26th year of bringing
together interventional cardiologists, vascular surgeons and other
healthcare professionals to focus on acquiring the latest knowledge
and product information related to interventional medicine and
vascular disease," said Bruce Barclay, president and CEO of Hansen
Medical. "We continue to build a growing body of positive clinical
data with the Magellan system, and live cases such as these provide
Hansen Medical with the opportunity to highlight to the
interventional vascular community how our technology can
significantly enhance endovascular procedures."
About the Magellan™ Robotic System
Hansen Medical's Magellan Robotic System is intended to be used
to facilitate navigation to anatomical targets in the peripheral
vasculature and subsequently provide a conduit for manual placement
of therapeutic devices. The Magellan Robotic System is designed to
deliver predictability to simple and complex endovascular
procedures. Since its commercial introduction in the U.S. and
Europe, the Magellan Robotic System has demonstrated its clinical
versatility in many cases in a broad variety of peripheral vascular
procedure types in centers across the US and Europe. The system is
based upon the flexible robotic technology incorporated in the
Sensei-X® Robotic Catheter System currently sold in the
U.S. and Europe, which has been used in over 13,000 patients, but
includes a number of key enhancements. In particular, the Magellan
Robotic System:
- Provides solid catheter stability for placement of
therapeutic devices.
- Is designed to enable predictable procedure times and
increased case throughput.
- Allows for independent, individual robotic control of the
distal tips of both the outer sheath and the inner
leader catheter, as well as robotic manipulation of standard
guidewires.
- Is designed to allow for sufficient extension inside the
body to access hard to reach peripheral anatomy.
- Preserves the open architecture featured in the Sensei
System to allow for the subsequent use of many 6F
therapeutic devices on the market today.
- Is designed to potentially reduce physician radiation
exposure and fatigue by employing a remote
physician workstation.
About Hansen Medical, Inc. Hansen Medical, Inc., based
in Mountain View, California, is a global leader in intravascular
robotics, developing products and technology designed to enable the
accurate positioning, manipulation and control of catheters and
catheter-based technologies. The Company's Magellan™ Robotic
System, 9Fr Magellan™ Robotic Catheter and related accessories,
which are intended to facilitate navigation to anatomical targets
in the peripheral vasculature and subsequently provide a conduit
for manual placement of therapeutic devices, have undergone both CE
marking and 510(k) clearance and are commercially available in the
European Union, and the U.S. In the European Union, the Company's
Sensei® X Robotic Catheter System and Artisan®
and Artisan Extend® Control Catheters are cleared for use
during electrophysiology (EP) procedures, such as guiding catheters
in the treatment of atrial fibrillation (AF), and the
Lynx® Robotic Ablation Catheter is cleared for the
treatment of AF. This robotic catheter system is compatible with
fluoroscopy, ultrasound, 3D surface map and patient
electrocardiogram data. In the U.S., the Company's Sensei X Robotic
Catheter System and Artisan and Artisan Extend Control Catheters
are cleared by the U.S. Food and Drug Administration for
manipulation and control of certain mapping catheters in EP
procedures. In the U.S., the Sensei X Robotic Catheter System is
not approved for use in guiding ablation procedures; this use
remains experimental. The U.S. product labeling therefore provides
that the safety and effectiveness of the Sensei X Robotic Catheter
System and Artisan and Artisan Extend Control Catheter for use with
cardiac ablation catheters in the treatment of cardiac arrhythmias,
including AF, have not been established. Additional information can
be found at www.hansenmedical.com.
Forward-Looking Statements This press release contains
forward-looking statements regarding, among other things,
statements relating to goals, plans, objectives, milestones and
future events. All statements, other than statements of historical
fact, are statements that could be deemed forward-looking
statements, including statements containing the words "plan,"
"expects," "potential," "believes," "goal," "estimate,"
"anticipates," and similar words. These statements are based on the
current estimates and assumptions of our management as of the date
of this press release and are subject to risks, uncertainties,
changes in circumstances and other factors that may cause actual
results to differ materially from the information expressed or
implied by forward-looking statements made in this press release.
Examples of such statements include statements about the potential
benefits of our technology and the value of our intellectual
property portfolio. Important factors that could cause actual
results to differ materially from those indicated by such
forward-looking statements include, among others: engineering,
regulatory, manufacturing, sales and customer service challenges in
developing new products and entering new markets; potential safety
and regulatory issues that could slow or suspend our sales; the
effect of credit, financial and economic conditions on capital
spending by our potential customers; the uncertain timelines for
the sales cycle for newly introduced products; the rate of adoption
of our systems and the rate of use of our catheters; the scope and
validity of intellectual property rights applicable to our
products; competition from other companies; our ability to recruit
and retain key personnel; our ability to manage expenses and cash
flow, and obtain additional financing; and other risks more fully
described in the "Risk Factors" section of our Quarterly Report on
Form 10-Q for the quarter ended September 30, 2013 filed with the
SEC on November 8, 2013 and the risks discussed in our other
reports filed with the SEC. Given these uncertainties, you should
not place undue reliance on the forward-looking statements in this
press release. We undertake no obligation to revise or update
information herein to reflect events or circumstances in the
future, even if new information becomes available.
Hansen Medical, Heart Design (Logo), Hansen Medical (with Heart
Design), Sensei and Lynx are registered trademarks, and Magellan
and NorthStar are trademarks of Hansen Medical, Inc. in the United
States and other countries.
Investor Contacts: Peter J. Mariani Chief Financial Officer
Hansen Medical, Inc. 650.404.5800 FTI Consulting, Inc. Brian
Ritchie 212.850.5683 Email Contact John Capodanno 212.850.5705
Email Contact
Hansen Medical, Inc. (MM) (NASDAQ:HNSN)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Hansen Medical, Inc. (MM) (NASDAQ:HNSN)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024